GE Healthcare Unidad Central De Radiofarmacia De Galicia
GE Healthcare Unidad Central De Radiofarmacia De Galicia is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxetan treatment in chemo-naïve adults with metastatic castration-resistant prostate cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) study
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with androgen receptor pathway inhibitors in patients with PSMA PET scan positive castration-resistant prostate cancer (PSMACare)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for GE Healthcare Unidad Central De Radiofarmacia De Galicia?
The 2026-10-09 snapshot links GE Healthcare Unidad Central De Radiofarmacia De Galicia to 2 distinct CTIS trials. Recorded services include Medicinal product management. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for GE Healthcare Unidad Central De Radiofarmacia De Galicia?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Urology. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to GE Healthcare Unidad Central De Radiofarmacia De Galicia conducted?
The linked trials record locations in 7 countries, including Germany, Spain, Netherlands, Czechia, France. These are trial locations, not confirmed office locations or countries where GE Healthcare Unidad Central De Radiofarmacia De Galicia delivered services.
What can this page tell me about GE Healthcare Unidad Central De Radiofarmacia De Galicia's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under GE Healthcare Unidad Central De Radiofarmacia De Galicia. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- GE Healthcare Unidad Central De Radiofarmacia De Galicia S.L.